Investor Information
Stéphane Bette,
Chief Executive Officer
Chief Executive Officer
Pierre Jérôme,
Chairman of the Board
Chairman of the Board
Dear Shareholders,
The Shareholder Meeting organized in May 2019 was an opportunity to review our 2018 results, to underline our latest progress and to share with you our perspectives on SpineGuard your company that we founded with the ambition, still intact, to make spine surgery safer and to exploit the full potential of DSG® (Dynamic Surgical Guidance) technology, unique in its ability to differentiate bony tissues in real-time and without using X-Rays.
Stock Information
Stock exchange information
- ISIN code: FR0011464452
- Stock Quote: ALSGD
- Number of shares: 10 364 420
- Sector: Medical technologies
- Principal Index: Alternext All-share
- Exchange: Euronext-Growth
- Place of listing: Euronext Paris (France)
- Eligibility to French PEA/SRD: Yes/No
- Eligibility French PEA-PME: Yes
Financial agenda
- 24 January 2019: 2018 Full-Year Sales
- 14 March 2019: 2018 Full-Year Results
- 11 April 2019: 2019 First-Quarter Sales
- 23 May 2019: Annual Shareholders Meeting
- 11 July 2019: 2019 First-Half Sales
- 18 Sep. 2019: 2019 First-Half Results
- 15 October 2019: 2019 Third-Quarter Sales
Analysts
- Biostrategic Research: Lionel Labourdette
Others
- Liquidity contract: Tradition Securities And Futures (TSAF)
- Auditors: Grant Thornton
- Listing Sponsor: Swiss Life Banque Privée
Shareholders structure
(May 20th, 2019)
Stock quotes
(In real time)
For any request do not hesitate to contact us